Ken Pettine's Biography

• Home
• |
• Register
• |
• Submissions
  • Submission Guidelines
  • Submissions
• |
• Agenda
• |
• Exhibition
• |
• Venue
• |
• Media
• |
• Dermatology
• |
• Cytometry
• |

Percutaneous Lumbar Intradiscal Injection of Autologous Bone Marrow Concentrated Cells Significantly Reduces Discogenic Pain through 12 Months

Tuesday, 22 April 2014 at 16:00

Add to Calendar ▼2014-04-22 16:00:002014-04-22 17:00:00Europe/LondonPercutaneous Lumbar Intradiscal Injection of Autologous Bone Marrow Concentrated Cells Significantly Reduces Discogenic Pain through 12 MonthsClinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California, USASELECTBIOenquiries@selectbiosciences.com

There are few non-surgical options for treating discogenic low back pain. Conservative therapy involves steroidal and non-steroidal injections, physical therapy, exercise, chiropractic treatments and systemic prescription pain relief, but usually doesn't provide durable pain relief. In this open label pilot study, twenty-six patients (median age 40 years; range 18-61) received autologous bone marrow concentrate (BMC) intra-discal injections (13 with one level, 13 with two levels injected). Pre-treatment Oswestry Disabilty Index (ODI) and Visual Analogue Scale (VAS) were performed to establish baseline pain scores (average 56.5 and 79.3, respectively). Cell analysis was performed on an aliquot of each patient's BMC. The average BMC comprised 121x10e6 TNC/mL including 3,019 CFU-F (synonymous with mesenchymal stem cells). The average ODI and VAS scores for 24/26 patients were reduced to 25.0 and 33.2 at 12 months (p?0.0001), respectively. Eight of 20 patients improved by one modified Pfirrmann grade, suggesting an improved hydration state in the disc.